NCT02373449View on ClinicalTrials.gov

Ketamine and fMRI for Neuropathic Pain

NACompletedINTERVENTIONAL
Enrollment

39

Participants

Timeline

Start Date

February 28, 2015

Primary Completion Date

December 31, 2019

Study Completion Date

December 31, 2020

Conditions
Neuralgia
Interventions
OTHER

RS-fMRI

Resting State-functional Magnetic Resonance Imaging. Protocols involving BOLD (blood oxygen level-dependent) and non-BOLD techniques will be used.

DRUG

Ketamine

Part of standard care. To be performed over five consecutive days (Monday to Friday) for six hours per day. A therapeutic range of 0.5 to 2.0 mg/kg/hour is targeted.

Trial Locations (1)

M5T2S8

Toronto Western Hospital, Toronto

All Listed Sponsors
lead

University Health Network, Toronto

OTHER

NCT02373449 - Ketamine and fMRI for Neuropathic Pain | Biotech Hunter | Biotech Hunter